Targeted therapy in the treatment of lung cancer in Iceland 2010–2023
Acta Oncologica · 2026
DOI: 10.2340/ao.v65.45118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Oncologica, 2026. Verfasst von Stefanía Ásta Tryggvadóttir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Hauptthemen laut MEDLINE: Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose: Lung cancer is the third most common malignancy in Iceland and remains the leading cause of cancer-related mortality. Lung cancer may harbor driver mutations affecting the function of Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), B-raf proto-oncogene (BRAF), RET proto-oncogene (RET), MET proto-oncogene (MET), and NTRK, which can influence the selection of targeted therapies and treatment outcomes. In Iceland, EGFR testing was initiated in 2005, and in 2016, multigene targeted panel became standard for tumor testing. The objective was to determine the uptake of testing and frequency of targeted mutations in lung cancer nationwide, the utilization of targeted therapies, and duration of such treatments.Patients/material and methods: Data on lung cancer diagnoses and stage at diagnosis were obtained from the Icelandic Cancer Registry, and molecular testing results were retrieved from the Department of Pathology at Landspitali University Hospital. Treatment data and outcomes were obtained from a central prescription/death registry and chart reviews.
Results
From 2010 to 2023, 2,528 patients were diagnosed with lung cancer, and 25% underwent molecular tumor testing, with 90% of stage IV adenocarcinomas tested in 2023. During comprehensive molecular testing in 2016–2023, targeted mutations were detected in 19.3% of tested patients: EGFR 9.9%, BRAF 2.3%, MET 2.7%, HER2 1.2%, ALK 2.7%, ROS1 0.6%, and RET 0.2%. Among patients found to have targeted mutations (2010–2023), 61.2% received targeted therapy; 33.8% remained on therapy for ≥ 12 months, and 13.5% for ≥ 24 months.
Interpretation
The use of molecular testing has increased significantly in the last 20 years, and the adaptation of new targeted therapies has been rapid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Icelandic Cancer Registry, Reykjavik, Iceland.
- Department of Oncology, Landspitali - The National University Hospital of Iceland.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Oncology, Landspitali - The National University Hospital of Iceland.
- Department of Oncology, Landspitali - The National University Hospital of Iceland; Molecular Pathology Unit; Department of Pathology.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Molecular Pathology Unit; Department of Pathology; University of Iceland; BioMedical Center (BMC).
ORCID-Profile: Bylgja Hilmarsdóttir, Sigurdis Haraldsdottir
Zitieren
APA
Tryggvadóttir, S. Á., Stefánsson, G. V., Birgisson, H., Gunnarsson, Ö., Guðbjartsson, T., Harðardóttir, H., Hilmarsdóttir, B., Barkardóttir, R. B., & Haraldsdottir, S. (2026). Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncologica. https://doi.org/10.2340/ao.v65.45118
Vancouver
Tryggvadóttir SÁ, Stefánsson GV, Birgisson H, Gunnarsson Ö, Guðbjartsson T, Harðardóttir H, et al. Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncologica. 2026. doi:10.2340/ao.v65.45118
BibTeX
@article{Tryggvadttir2026,
author = {Tryggvadóttir, Stefanía Ásta and Stefánsson, Guðlaugur V and Birgisson, Helgi and Gunnarsson, Örvar and Guðbjartsson, Tómas and Harðardóttir, Hrönn and Hilmarsdóttir, Bylgja and Barkardóttir, Rósa B and Haraldsdottir, Sigurdis},
title = {Targeted therapy in the treatment of lung cancer in Iceland 2010–2023},
journal = {Acta Oncologica},
year = {2026},
doi = {10.2340/ao.v65.45118}
}
EUVIMED